FAKTOR-OPTIONSSCHEIN - NOVO-NORDISK B | Delayed Börse Stuttgart 05:44:48 2024-06-27 EDT | ||
| 0.14 EUR | +7.69% |
|
| Current month | -71.11% | ||
| 1 month | -68.29% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-27 | 0.14 | +7.69% |
| 24-06-26 | 0.13 | +30.00% |
| 24-06-25 | 0.1 | -47.37% |
| 24-06-24 | 0.19 | 0.00% |
| 24-06-21 | 0.19 | +11.76% |
Delayed Quote Börse Stuttgart
Last update June 27, 2024 at 05:44 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SW7B9Z |
| ISIN | DE000SW7B9Z0 |
| Date issued | 2024-03-07 |
| Strike | 857.4 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.88 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 9.58 € |
|---|---|
| Lowest since issue | 0.1 € |
| Spread | 0.01 € |
| Spread % | 6.67% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,007
DKK
Average target price
937.9
DKK
Spread / Average Target
-6.86%
- Stock Market
- Certificates
- Certificat
